Crossmark

Structured Qualitative Benefit-Risk Assessment to Inform Go/No-Go Decisions for Phase III Testing of Pharmaceutical Products

Crossref DOI link: https://doi.org/10.1007/s40290-015-0132-4

Published Online: 2016-01-13

Published Print: 2016-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wolka, Anne

Radawski, Christine

Noel, Rebecca
Funding

Funding for this research was provided by:

Eli Lilly and Company (US)
License Information

Text and Data Mining valid from 2016-01-13